News and Trends 12 May 2023 DiogenX raises €27.5M for “breakthrough” diabetes treatment DiogenX, a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes, has announced the successful completion of a €27.5 million ($30 million) Series A financing round. New investors Roche Venture Fund, Eli Lilly and Company and Omnes joined this round alongside existing investors Boehringer Ingelheim Venture Fund (BIVF), JDRF T1D Fund, […] May 12, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 May 2023 Cell and gene therapy company NewBiologix exits stealth with $50M NewBiologix SA has emerged from stealth as a technology innovation company developing a proprietary and breakthrough platform for the advanced engineering of cell lines used to manufacture gene and cell therapies. The company’s DNA-based platform is being developed to address key manufacturing challenges associated with the production of recombinant adeno-associated virus (rAAV) vectors used to […] May 12, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 May 2023 Gene & cell therapy manufacturer Ascend launches with more than $130M Ascend Gene & Cell Therapies (Ascend), a company innovating manufacturing processes to improve quality, potency, safety and cost enabling better reach for gene therapy technologies, has launched as a facilitator for gene therapy companies to help translate product ideas into clinical programs. Ascend Gene & Cell Therapies offers process development, clinical manufacturing, and analytical and […] May 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 5 May 2023 The biggest private biotech investments in April 2023 April 2023 saw the companies Orbital Therapeutics, Sangon Biotech, and Alentis Therapeutics bag the biggest biotech investments of the month. Around the world, oncology, drug discovery, food and biomaterials attracted the biggest funding rounds. With reports of venture capital investments in biotech and pharma hitting a more than three-year low last quarter, private biotech fundraising […] May 5, 2023 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 5 May 2023 Convergent Therapeutics to use $90M funding to treat cancer with radiopharmaceuticals Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment of cancer, today announced the completion of a $90 million Series A financing. The funding was led by OrbiMed and RA Capital Management with participation from Invus. The financing will support the development of a pipeline of novel […] May 5, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Apr 2023 Mezzion Pharma raises $40M for treatment option for heart surgery patients Mezzion Pharma, a rare disease focused pharmaceutical company, has secured nearly $40 million to fund FUEL-2, its confirmatory phase 3 clinical trial, along with future commercialization and regulatory submissions in other countries including Europe. Mezzion Pharma is looking to bring to market JURVIGO (udenafil), a highly selective, unique and potent phosphodiesterase type 5 (PDE-5) inhibitor, […] April 28, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Apr 2023 ADC firm Adcentrx Therapeutics aims for clinic after $38M boost Antibody-drug conjugate (ADC) biotech company Adcentrx Therapeutics has closed a $38 million Series A+ financing. The round was led by Eight Roads Ventures, with participation from F-Prime Capital, ABio-X, Delta Capital, Trinity Innovation Fund, and other strategic investors. Life Venture Partners and Lighthouse Capital acted as Adcentrx’s financial advisors. Adcentrx Therapeutics intends to use the […] April 28, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Apr 2023 Vedanta Biosciences raises $106.5M for microbiome therapy Vedanta Biosciences, a clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, has raised $106.5 million. The funds will support pivotal-stage development of the U.S. company’s lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI), and a phase 2 study of VE202 for ulcerative colitis, among […] April 27, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Apr 2023 LifeArc launches £40M funding call to create Translational Rare Disease Centres LifeArc is inviting applications from academic institutions for its latest £40 million ($49.8 million) initiative to fund four or five new Translational Rare Disease Centres in the U.K., along with a separate co-ordinating hub. LifeArc, which is a self-funded, non-profit medical research charity, specializes in early-stage translation – the advancement of scientific discoveries towards patient […] April 24, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Apr 2023 Hasten raises $315M for acquisitions and pipeline development CBC Group, Asia’s largest healthcare-dedicated investment firm headquartered in Singapore, and Hasten Biopharmaceutic Company Limited, have completed a $315 million fundraising round for Hasten. Hasten is a Chinese biopharma company backed by CBC, Hefei Industry Investment Group, and Feidong County of Hefei City. The fundraising round was co-led by CBC and Abu Dhabi sovereign wealth […] April 20, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2023 Calida Therapeutics launches to tackle thrombo-inflammatory disorders Calida Therapeutics, a preclinical stage biotech company specializing in thrombo-inflammatory disorders, has announced its incorporation in Paris, France. Calida Therapeutics has already raised €2 million ($2.17 million) in seed funding from venture capital company AdBio partners. The funds will be used to conduct additional in vivo proofs of concept and select a lead candidate. Calida […] April 11, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2023 Intracellular drug delivery startup Vitarka Therapeutics raises £1.27M Vitarka Therapeutics, which focuses on non-viral drug delivery technology, has raised £1.27 million ($1.58 million) in equity from venture capital firm SOSV, the UK Innovation & Science Seed Fund (UK12S) and grant funding from Innovate UK. Founded in 2021 by Vineeta Tripathi, Vitarka Therapeutics is developing combination medicines using RNAi therapies and a non-viral drug […] April 11, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email